Hormone Therapy

DRUG19 trials

Sponsors

Burzynski Research Institute, Intarcia Therapeutics, Robert H. Lurie Cancer Center, Eastern Cooperative Oncology Group, M.D. Anderson Cancer Center

Conditions

Adenocarcinoma of the ProstateAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast CancerBreast NeoplasmsEarly Breast CancerEarly Stage HER2-Positive Breast Carcinoma

Phase 1

Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

Active, not recruitingNCT04619069

Sunnybrook Health Sciences CentreProstate Cancer

Start: 2020-10-27End: 2027-10-31Updated: 2025-04-17

Phase 2

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

WithdrawnNCT00003517

Burzynski Research InstituteAdenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer +1

Updated: 2013-07-10

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

WithdrawnNCT00080613

Robert H. Lurie Cancer CenterStage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer +1

Updated: 2013-07-10

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

WithdrawnNCT00227773

Eastern Cooperative Oncology GroupGastrointestinal Carcinoid Tumor, Islet Cell Carcinoma

Updated: 2015-10-08

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

CompletedNCT02366130

M.D. Anderson Cancer CenterBreast Cancer

Start: 2015-02-11End: 2020-12-16Updated: 2021-10-07

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

RecruitingNCT04915508

Jonsson Comprehensive Cancer CenterProstate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8 +3

Start: 2021-06-23End: 2027-08-01Target: 102Updated: 2025-06-22

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

Active, not recruitingNCT05041842

UNICANCERMetastatic Breast Cancer With a Isolated Brain Progression

Start: 2021-12-17End: 2026-04-30Updated: 2025-11-17

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

RecruitingNCT07112053

University of WashingtonAnatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma

Start: 2025-11-17End: 2028-12-31Target: 40Updated: 2026-03-09

Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy

Not yet recruitingNCT07237269

University of NebraskaProstate Cancer

Start: 2026-02-01End: 2033-02-01Target: 140Updated: 2025-11-19

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Active, not recruitingNCT07407920

M.D. Anderson Cancer CenterAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma +1

Start: 2025-10-09End: 2027-09-30Target: 120Updated: 2026-02-12

Phase 3

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

CompletedNCT00044291

Intarcia TherapeuticsBreast Neoplasms, Neoplasms, Hormone-dependent

Start: 2002-06-30End: 2006-01-31Updated: 2015-07-31

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

TerminatedNCT00097344

Intarcia TherapeuticsBreast Neoplasms, Neoplasms, Hormone-Dependent

Start: 2004-12-31End: 2006-08-31Target: 842Updated: 2007-08-23

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

CompletedNCT03493854

Hoffmann-La RocheEarly Breast Cancer

Start: 2018-06-14End: 2023-06-02Updated: 2024-06-26

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

CompletedNCT04024462

Hoffmann-La RocheHER2-positive Early Breast Cancer

Start: 2020-02-05End: 2026-01-19Updated: 2026-02-20

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

RecruitingNCT04134260

NRG OncologyProstate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8 +2

Start: 2020-04-16End: 2026-11-01Target: 586Updated: 2026-01-14

Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer

RecruitingNCT05448547

Sven LöffelerProstate Cancer

Start: 2022-11-04End: 2036-12-31Target: 980Updated: 2025-07-01

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

RecruitingNCT05717166

David PalmaMetastatic Tumor

Start: 2023-10-06End: 2029-04-30Target: 180Updated: 2025-12-31

Unknown Phase

The Efficacy of G-CSF Against Adhesion Reformation After Hysteroscopic Adhesiolysis

Sir Run Run Shaw HospitalIntrauterine Adhesion

Start: 2016-08-31End: 2019-12-31Target: 240Updated: 2018-01-05

Metabolic and Physiologic Responses to Hormone Therapy in Transgender and Gender Diverse People

RecruitingNCT06083766

Mayo ClinicEffects of GAHT, on Skeletal Muscle in TGD

Start: 2024-01-04End: 2026-07-31Target: 24Updated: 2025-11-10

Related Papers

A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol

BMC Palliative Care2024-09-0710 citations

114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study

ESMO Open2024-05-01

Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non‐metastatic high‐risk prostate cancer (SPCG 19/GRand‐P)

British Journal of Urology2024-03-122 citations

Abstract OT1-10-01: Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after local therapy of isolated brain progression: InTTercePT, a UCBG/GINECO study

Cancer Research2023-03-01

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

JAMA Oncology2022-12-01181 citations

Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.

2022-10-074 citations

Intrauterine administration of G-CSF for promoting endometrial growth after hysteroscopic adhesiolysis: a randomized controlled trial

Human Reproduction2022-01-2724 citations

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

Cancer Chemotherapy and Pharmacology2021-06-0914 citations

INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.

Journal of Clinical Oncology2021-02-206 citations

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.

2020-12-21109 citations

Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study

Cancer Research2020-02-158 citations

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer

Cancer Medicine2019-12-1831 citations

Abstract P1-18-04: CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis

Cancer Research2019-02-151 citations

Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis.

Journal of Clinical Oncology2018-05-206 citations

Abstract P1-16-02: Phase II study of the feasibility and safety of radium-223 dichloride in combination with hormonal therapy and denosumab for the treatment of patients with hormone receptor-positive breast cancer with bone-dominant metastasis

Cancer Research2018-02-15